BPC-157 is a 15-amino acid peptide isolated from a sequence in human gastric juice. Since the early 1990s, a research group led by Predrag Sikiric at the University of Zagreb has published the majority of the available preclinical data on this compound, with a particular focus on gastrointestinal protection, tendon and muscle repair, and angiogenesis. The peptide has not progressed to significant human clinical trials, and most evidence remains limited to rodent injury models.
Mechanism of Action
The precise signalling pathways through which BPC-157 exerts its effects remain under investigation. Three pathways have the strongest preclinical support.
Angiogenesis
BPC-157 upregulates vascular endothelial growth factor (VEGF) expression in damaged tissue. Chang et al. (2011) demonstrated that BPC-157 accelerated Achilles tendon healing in rats by promoting new vessel formation, coupled with activation of the FAK-paxillin signalling cascade. This pro-angiogenic effect appears to be a central mechanism linking many of the peptide’s observed tissue-repair properties.
Nitric Oxide System
In a 1999 study published in the European Journal of Pharmacology, Sikiric et al. (1999) showed that BPC-157 interacted with the nitric oxide (NO) system in rats, counteracting the effects of NO synthase inhibitors and maintaining vascular integrity under stress conditions. The peptide appears to stabilise endothelial cell function when NO signalling is disrupted.
Growth Hormone Receptor Interaction
Some in vitro work indicates BPC-157 may bind or modulate the growth hormone receptor pathway. This has been proposed as a contributing factor in its tissue-repair activity, though the data is preliminary and the interaction is not well characterised.
Cytoprotective Properties
Gastric mucosa protection was the first biological activity described for BPC-157. Sikiric et al. (1993) reported protection against ethanol-induced and NSAID-induced gastric lesions in rodent models, consistent with its origin from gastric juice proteins. This cytoprotective activity has since been confirmed by multiple groups using stress-induced, ischaemia-reperfusion, and cysteamine-induced ulcer models.
Key Research
Wound Healing
Published data on BPC-157 and wound closure covers several tissue types in rodent models:
- Skin wounds: Staresinic et al. (2003) (PMID: 12784359) reported accelerated cutaneous wound closure and improved collagen organisation in rats treated with BPC-157
- Muscle injuries: The same group showed reduced fibrosis and faster functional recovery in crushed rat gastrocnemius muscle
- Nerve injuries: Peripheral nerve transection models in rats showed improved axonal regeneration and functional recovery with BPC-157 treatment
Gut Permeability
BPC-157’s gastrointestinal effects are among the most consistently reported findings:
- Sikiric et al. (1999) (PMID: 10548376) demonstrated that BPC-157 maintained intestinal mucosal integrity in rats exposed to NSAIDs and ethanol
- Tight junction proteins (ZO-1, occludin) showed preserved expression in BPC-157-treated intestinal epithelium in a 2012 in vitro study
- The peptide’s protective effects span both gastric and intestinal segments, as documented across multiple Zagreb group publications from 1993 to 2014
Tendon and Ligament Repair
Achilles tendon transection and defect models in rats have been the primary injury models used:
- Chang et al. (2011) found that BPC-157 improved biomechanical strength, collagen bundle organisation, and vessel density in transected rat Achilles tendons
- Staresinic et al. reported enhanced fibroblast migration and proliferation at the repair site
- BPC-157 counteracted the negative effects of corticosteroid (methylprednisolone) injection on tendon healing in rat models, as shown by Sikiric et al. (2010)
Central Nervous System
Neuroprotection studies remain early-stage:
- Rat models of traumatic brain injury showed reduced lesion size and improved neurological scores with BPC-157 treatment (Jelovac et al., 1998; PMID: 9803395)
- The peptide interacts with both serotonin and dopamine systems in rodent brain, based on behavioural and neurochemical assays
- These findings are hypothesis-generating but have not moved beyond animal models
Australian Research Context
BPC-157 holds no approval from the Therapeutic Goods Administration (TGA) for any therapeutic indication and does not appear on the Australian Register of Therapeutic Goods (ARTG). The peptide is unregulated in Australia for research use but cannot be marketed or supplied for human therapeutic purposes.
The current evidence base consists almost entirely of animal studies. Rodent data does not automatically translate to human outcomes - interspecies differences in pharmacokinetics, receptor affinity, and tissue biology mean that the dose-response and efficacy profiles seen in rats may not apply to humans. Clinical trials in humans remain absent.
Research Limitations
Several constraints define the current BPC-157 literature:
- Published work is predominantly in rodent models (rats, mice)
- No randomised, placebo-controlled clinical trials exist in humans
- The bulk of the literature comes from one research centre in Zagreb, Croatia
- Human dose-response data does not exist
- Long-term safety profiles are unknown
- Peptide stability, oral bioavailability, and optimal delivery methods are unresolved
Interpret the preclinical data with these constraints in mind.
Why Is Research Limited on These Compounds?
Many peptides discussed in the tissue repair field, including BPC-157 and TB-500, are naturally occurring amino acid sequences. A peptide found in human gastric juice (BPC-157) or thymic tissue (thymosin beta-4) cannot be patented in its native form.
Pharmaceutical investment in drug development follows a predictable economic logic: companies fund clinical trials when patent protection and market exclusivity allow them to recoup the cost of Phase I, II, and III studies, which routinely exceed hundreds of millions of dollars. Short, naturally occurring peptide sequences lack the exclusivity that makes this investment viable.
This does not mean the compounds are ineffective or scientifically unimportant. It means the economic incentive structure that drives large-scale clinical development does not apply. The practical consequence is that most published research on BPC-157 comes from academic laboratories - principally the University of Zagreb - and publicly funded studies, rather than from industry-sponsored clinical programs. Sikiric et al. (2010) review this context in their 2010 preclinical summary.
For researchers in Australia, the TGA’s regulatory framework for unapproved therapeutic goods defines the legal boundaries for accessing and using such compounds.
Related Compounds
- TB-500 (Thymosin Beta-4) - Often studied alongside BPC-157 in tissue repair research; acts through actin regulation rather than angiogenesis
- GHK-Cu - A copper peptide with data on wound healing and collagen synthesis
- GLP-1 Peptides - Overview of GLP-1 receptor agonist research
For research literacy and educational purposes only. This content does not constitute medical advice or therapeutic recommendation. Consult a qualified healthcare professional for medical decisions.